Fred Alger Management, LLC Vericel Corp Transaction History

Fred Alger Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$17.65 - $27.37 $20.5 Million - $31.8 Million	-1,161,353 Reduced 59.72%	783,225 $20.6 Million
Q3 2022 Nov 14, 2022	BUY	$22.62 - $32.54 $238,799 - $343,524	10,557 Added 0.55%	1,944,578 $45.1 Million
Q2 2022 Aug 15, 2022	SELL	$22.88 - $39.45 $18.8 Million - $32.5 Million	-822,755 Reduced 29.84%	1,934,021 $48.7 Million
Q1 2022 May 16, 2022	SELL	$31.69 - $43.29 $14.2 Million - $19.3 Million	-446,586 Reduced 13.94%	2,756,776 $105 Million
Q4 2021 Feb 14, 2022	SELL	$35.2 - $52.6 $6.1 Million - $9.12 Million	-173,314 Reduced 5.13%	3,203,362 $126 Million
Q3 2021 Nov 15, 2021	BUY	$46.35 - $59.75 $586,142 - $755,598	12,646 Added 0.38%	3,376,676 $165 Million
Q2 2021 Aug 16, 2021	BUY	$47.2 - $67.81 $30.2 Million - $43.4 Million	639,959 Added 23.49%	3,364,030 $177 Million
Q1 2021 May 17, 2021	BUY	$30.93 - $59.48 $84.3 Million - $162 Million	2,724,071 New	2,724,071 $151 Million
Q1 2019 May 14, 2019	SELL	$16.23 - $20.29 $146,070 - $182,610	-9,000 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$10.77 - $18.44 $96,930 - $165,960	9,000 New	9,000 $157,000

285

49.3M

91.8K

23.2K

Ticker VCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,178,000
Market Cap $2.92B
Description
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for t...

Get notified when there are updates to the investment portfolio of Fred Alger Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Fred Alger Management, LLC with notifications on news.